Opus Genetics, Inc. (IRD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Opus Genetics, Inc. (IRD) has a cash flow conversion efficiency ratio of -0.641x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.83 Million) by net assets ($15.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Opus Genetics, Inc.'s balance sheet to measure how much of total assets are equity-financed.
Opus Genetics, Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Opus Genetics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Opus Genetics, Inc. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Opus Genetics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Opus Genetics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Fengshan Group Co Ltd
SHG:603810
|
-0.013x |
|
Aviat Networks Inc
NASDAQ:AVNW
|
-0.006x |
|
H+H International A/S
CO:HH
|
0.054x |
|
Haibo Heavy Engineering Science and Technology Co Ltd
SHE:300517
|
0.031x |
|
Ningbo Tianyi Medical Appliance Co. Ltd.
SHE:301097
|
N/A |
|
JNK India Ltd
NSE:JNKINDIA
|
0.018x |
|
Dharma Polimetal Tbk PT
JK:DRMA
|
0.093x |
|
Dustin Group AB
ST:DUST
|
0.054x |
Annual Cash Flow Conversion Efficiency for Opus Genetics, Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Opus Genetics, Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see IRD market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.35 Million | $-35.25 Million | -2.297x | +39.61% |
| 2024-12-31 | $6.72 Million | $-25.58 Million | -3.804x | -16970.76% |
| 2023-12-31 | $49.91 Million | $-1.11 Million | -0.022x | -107.20% |
| 2022-12-31 | $46.24 Million | $14.31 Million | 0.310x | +135.51% |
| 2021-12-31 | $22.22 Million | $-19.37 Million | -0.872x | -272.70% |
| 2020-12-31 | $-13.47 Million | $-6.80 Million | 0.505x | +6.20% |
| 2019-12-31 | $-7.56 Million | $-3.59 Million | 0.475x | -- |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 t… Read more